sb 203580 has been researched along with farnesol in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (farnesol) | Trials (farnesol) | Recent Studies (post-2010) (farnesol) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 1,161 | 9 | 404 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kabir, AN; Marber, MS; Mockridge, JW; Rakhit, RD; Saurin, A | 1 |
1 other study(ies) available for sb 203580 and farnesol
| Article | Year |
|---|---|
Role of G proteins and modulation of p38 MAPK activation in the protection by nitric oxide against ischemia-reoxygenation injury.
Topics: Adenoviridae; Animals; Animals, Newborn; Apoptosis; Blotting, Western; Cell Survival; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Farnesol; GTP-Binding Proteins; Humans; Imidazoles; Ischemic Preconditioning, Myocardial; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Myocardium; Nitric Oxide; Organophosphonates; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Binding; Protein Isoforms; Protein Kinase C; Pyridines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Time Factors | 2001 |